GSK's $31 Billion Bet Starts With a Cancer Most Companies Won't Touch

Perhaps most importantly, the safety profile looked manageable. Interstitial lung disease (ILD), the toxicity boogeyman that haunts ADC development, showed up in only about 4% of patients.

Why Gynecologic Cancers Are the Smart Play

If ADCs are the hottest modality in oncology right now, gynecologic cancers are one of the least crowded arenas to deploy them.

The biggest ADC players have been fighting over breast cancer, lung cancer, and blood cancers for years. Daiichi Sankyo and AstraZeneca's Enhertu is the top-selling ADC on the market, driven mostly by HER2-positive breast and lung cancers. Gilead's Trodelvy has carved out its own territory in breast cancer. Pfizer, Roche, and others are piling in.

But gynecologic cancers? That's relatively open field. By targeting B7-H4, GSK sidesteps the slugfest and goes after a patient population desperate for better options. It's the biotech equivalent of zigging when everyone else zags.

The global ADC market is projected to reach somewhere between $25 billion and $32 billion by the early 2030s, depending on which forecast you trust. GSK doesn't need to win the whole market. It just needs to own a meaningful corner of it.

GSK's Bigger ADC Playbook

Mo-Rez isn't GSK's only card in the ADC deck. The company has been quietly assembling an entire portfolio.

Blenrep (belantamab mafodotin) targets BCMA in multiple myeloma and is already on the market. Risvutatug rezetecan, a B7-H3-targeted ADC also licensed from Hansoh Pharma, is heading toward pivotal trials in small-cell lung cancer with clinical trials expected to start mid-2026. And in October 2025, GSK agreed to a deal worth up to $357 million (including milestones) to acquire a preclinical ADC from Syndivia targeting metastatic castration-resistant prostate cancer, a market set to double as prostate cancer cases are projected to reach 2.9 million annually by 2040.

The strategy is what GSK calls a "two-speed" approach: broad sourcing at the discovery level, selective bets on high-potential assets further along. It's less "throw everything at the wall" and more "pick your shots carefully, then swing hard."

The company has identified 14 scale innovation opportunities expected to launch before 2031, each with peak annual sales potential exceeding £2 billion.

The Risks Nobody Should Ignore

ADC development is littered with expensive failures. The technology is elegant in theory but punishing in practice. Getting the right antibody, the right linker chemistry, the right payload, and the right drug-to-antibody ratio is like tuning a four-part harmony where one wrong note can be fatal (sometimes literally).

Aggregation issues can wreck manufacturing at scale. Toxicity profiles can shift dramatically between Phase 1 and Phase 3. And competitive intensity in the broader ADC space is ferocious; AstraZeneca committed $1.5 billion in late 2024 just to build a single commercial-scale ADC manufacturing facility in Singapore.

GSK's oncology business showed real momentum in Q4 2025, with 42% growth in oncology revenue and 17% growth across Specialty Medicines overall. But translating early-phase excitement into late-stage success is where most ADC stories fall apart.

The Bottom Line

GSK is making its boldest oncology bet in years, and it's doing it in cancers that most big pharma companies have overlooked. The Phase 1b data is genuinely impressive, particularly for populations with limited treatment options and grim survival statistics.

But five Phase 3 trials simultaneously? That's an enormous resource commitment and a signal that GSK believes Mo-Rez can be a franchise-defining asset, not just another pipeline entry. Abdullah described a "data-driven approach" with consistent efficacy and safety from two independent datasets justifying the rapid expansion.

Whether "scientific courage" translates into commercial success won't be clear for a couple of years. For now, though, GSK has made one thing unmistakable: it wants to be a major player in the ADC wars, and it's betting gynecologic oncology is the battlefield where it can win.

Two Biotechs Just Rang the IPO Bell on the Same Day

Seaport Therapeutics and Hemab Therapeutics both filed $100 million IPOs on the exact same day, targeting depression and rare bleeding disorders respectively. Their simultaneous filings say a lot about where the biotech IPO market stands in Q2 2026.